HopeStage
Back to overview

Schizophrenia studies

Topics
More filters

Schizophrenia

Schizophrenia can affect how a person perceives reality, thinks and feels, sometimes involving hearing voices or holding unusual beliefs.

4505studies shown
Showing 1,057-1,068 of 4,505
Drug study icon
CompletedNCT04001114

Cigarette Smoking in Smokers With and Without Schizophrenia

Official study title

Cigarette Smoking in Smokers With and Without a Diagnosis of Schizophrenia

This study has finished and is no longer accepting participants.

In Catonsville
SchizophreniaInterventional studyAges 18–60
Countries
United States
Sponsor
University of Maryland, Baltimore
Behavioral study icon
CompletedNCT07378150

Clay Therapy in Schizophrenia Patients

Official study title

The Effect of Clay Therapy on Functional Improvement and Individual and Social Performance in Schizophrenic Patients

This study has finished and is no longer accepting participants.

In Kütahya
SchizophreniaInterventional studyAges 18+
Countries
Türkiye
Sponsor
Kutahya Health Sciences University
Drug study icon
CompletedNCT00137020

Clinical Effect Of Cross Titration Of Antipsychotics With Ziprasidone In Schizophrenia Or Schizoaffective Disorder

Official study title

A Multi-Center Study to Examine The Clinical Effects of Cross Titration of Antipsychotics With Ziprasidone in Subjects With Schizophrenia or Schizoaffective Disorder

This study has finished and is no longer accepting participants.

Multiple locations, including Alexandria
SchizophreniaMedication studyAges 18–65
Countries
Egypt, Greece, Jordan, + 6 others
Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Drug study icon
TerminatedNCT03593213

Study Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in a Dose-Reduction Paradigm in the Prevention of Relapse in people with Schizophrenia

Official study title

A Double-Blind, Placebo-Controlled, Randomized Withdrawal, Multicenter Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in a Dose-Reduction Paradigm in the Prevention of Relapse in Patients With Schizophrenia

This study ended early.

Multiple locations, including Bentonville
SchizophreniaMedication studyAges 18–64
Countries
United States, Bulgaria, Malaysia, + 7 others
Sponsor
AbbVie
Drug study icon
CompletedNCT04846868

study of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-1)

What is this study about?

Researchers compared Iclepertin and placebo to find out how the approaches affected memory, attention and other thinking skills in people with schizophrenia.

This study has finished and is no longer accepting participants.

Multiple locations, including Garden Grove
SchizophreniaMedication studyAges 18–50
Countries
United States, Australia, Canada, + 14 others
Sponsor
Boehringer Ingelheim
Drug study icon
CompletedNCT04846881

study of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-2)

What is this study about?

Researchers compared Iclepertin and placebo to find out how the approaches affected memory, attention and other thinking skills in people with schizophrenia.

This study has finished and is no longer accepting participants.

Multiple locations, including Bellflower
SchizophreniaMedication studyAges 18–50
Countries
United States, France, Argentina, + 15 others
Sponsor
Boehringer Ingelheim
Behavioral study icon
CompletedNCT05341804

Cognitive and Balance Dual Task Training for People With Schizophrenia

Official study title

Cognitive and Balance Dual Task Training for People With Schizophrenia - Program System Development and Effectiveness Analysis

This study has finished and is no longer accepting participants.

In Kaohsiung City
SchizophreniaBehavioural studyAges 40–75
Countries
Taiwan
Sponsor
Kaohsiung Medical University Chung-Ho Memorial Hospital
Device study icon
CompletedNCT06155786

Cognitive Effects of tDCS and tRNS in Schizophrenia

Official study title

Cognitive Effects of Transcranial Direct Current Stimulation (tDCS) and Transcranial Random Noise Stimulation (tRNS) in Schizophrenia: A Random, Crossover Study

This study has finished and is no longer accepting participants.

Multiple locations, including Tehran
SchizophreniaDevice studyAges 18–50
Countries
Iran
Sponsor
The National Brain Mapping Laboratory (NBML)

Registry coverage

We gather information about mental health clinical trials from the public registries we index. Coverage is still expanding, so some studies may not appear yet.